Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $66.00.

A number of research firms have recently commented on CLDX. Guggenheim increased their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. TD Cowen started coverage on Celldex Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd.

Celldex Therapeutics Stock Up 1.8 %

CLDX stock opened at $41.79 on Friday. The business has a 50 day moving average of $41.16 and a 200 day moving average of $34.32. The firm has a market cap of $2.34 billion, a PE ratio of -14.36 and a beta of 1.52. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million during the quarter, compared to analyst estimates of $1.20 million. On average, research analysts expect that Celldex Therapeutics will post -2.93 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of CLDX. Wellington Management Group LLP grew its position in shares of Celldex Therapeutics by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock valued at $149,484,000 after acquiring an additional 300,406 shares during the period. GSA Capital Partners LLP grew its holdings in Celldex Therapeutics by 192.0% during the third quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company’s stock valued at $1,231,000 after purchasing an additional 29,404 shares during the period. Kynam Capital Management LP increased its position in Celldex Therapeutics by 84.5% in the second quarter. Kynam Capital Management LP now owns 2,600,000 shares of the biopharmaceutical company’s stock worth $88,218,000 after buying an additional 1,190,549 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Celldex Therapeutics by 1,481.7% in the third quarter. SG Americas Securities LLC now owns 78,011 shares of the biopharmaceutical company’s stock worth $2,147,000 after buying an additional 73,079 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Celldex Therapeutics by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock valued at $9,950,000 after buying an additional 10,818 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.